

Thermo Fisher announces new collaborations for clinical biomarker discovery

15 September 2020 | News

Agreements with AstraZeneca and the University of Nebraska Medical Center showcase new workflows to improve the throughput, robustness and standardization of clinical biomarker analysis



Thermo Fisher Scientific, the world leader in serving science, has announced new collaborations of the Thermo Fisher Precision Medicine Science Center (PMSC) with AstraZeneca and the University of Nebraska Medical Center as part of its ongoing development of innovative solutions for unmet needs in clinical biomarker discovery.

The new alliances strengthen the PMSC's mission of creating standardized workflows with pharma and academic partners to streamline the transition from biomarker research to clinical implementation, creating new opportunities for precision medicine.

Ongoing and planned studies with both AstraZeneca and the University of Nebraska Medical Center will utilize standardized plasma protein profiling workflows, including Thermo Fisher's newly developed ultra-high throughput plasma protein profiling (uHTPPP) workflow, for biomarker discovery, for a range of conditions.

The standardized workflows consist of automated sample preparation for untargeted and targeted methods in combination with the [Thermo Scientific Orbitrap Exploris 480](#) and [Thermo Scientific Orbitrap Exploris 240 mass spectrometers](#).

Subsequently, the University of Nebraska Medical Center is collaborating with Thermo Fisher's PMSC to utilize the company's standardized plasma protein profiling workflows to analyze clinical samples in an aneurysm study. The study is supported by the National Institutes of Health-National Institute on Aging (NIH-NIA) and done in collaboration with Vanderbilt University, the University of Maryland and the University of Wisconsin.